ORHUB INC - ORHB STOCK NEWS

HippoFi, Inc. (formerly ORHub, OTC PINK:ORHB) kicks off 2023 with remarkable sales growth in its PUR Biologics product line. Over the past six weeks, the company expanded its sales channels by 28%, driven by strong customer demand. Executive Chairman CJ Wiggins highlighted the potential for ongoing growth, positioning HippoFi as a leader in biologics. The company attributes its success to robust relationships with surgeons and distributors, aiming to significantly capture market share in the next year.

HippoFi, trading under the symbol ORHB, has launched PURbridge™, an advanced synthetic bioactive glass product aimed at the spine surgery market, projected to reach $18 billion in 2023. This new biologic product targets the need for effective new bone growth in lumbar and thoracic spine fusion surgeries. Its unique composition melds bioactive glass, Tri-pore NanoCrystals™, and collagen for enhanced healing outcomes. CEO CJ Wiggins emphasizes the company's commitment to leading in regenerative therapeutics and digital payment solutions in the surgical implant sector.

HippoFi, Inc. (OTC PINK:ORHB) announced a strategic agreement with Precision Spine, Inc. to enhance its sales strategy by leveraging Precision’s established channels. This partnership aims to accelerate revenue growth through the sale of the PUR Biologics product line amidst a robust market expected to reach $75B by 2030. The collaboration is poised to improve brand recognition and sales through Precision's network of over 280 hospitals and 340 spine surgeons. CEO CJ Wiggins highlighted the significant potential of biologics in the orthopedic sector.

HippoFi has rebranded and outlined recent achievements in its press release dated September 7, 2022. The company aims to capitalize on the fintech, biotech, and AI markets by leveraging its sales expertise and new technologies. Key milestones include the launch of a new surgical software platform, partnerships with industry leaders, and acquisition of PUR Biologics for innovative regenerative technologies. The company anticipates revenue growth and is focused on expanding its market reach with a dedicated sales strategy and exclusive agreements.

ORHub has rebranded itself as HippoFi, highlighting its focus on fintech and healthcare innovation. The company aims to tap into multibillion-dollar markets in FINTECH, BIOTECH, and ARTIFICIAL INTELLIGENCE, targeting an annual US market spend of nearly $300 billion. HippoFi is moving to enhance partnerships, pursue acquisitions, and deploy advanced digital solutions to improve patient care and operational efficiency. The company plans to upgrade from OTC to OTC-QB status and aims for a future NASDAQ listing while continuing under the ticker ORHB.

ORHub plans to launch its new bone growth product, PUR Pillars, designed specifically for spine surgery, in early Q4 2022. This product addresses the challenges of spinal fusion surgeries, which total approximately 950,000 annually in the U.S., with a growth rate of 6%. The market for bone growth products is estimated to exceed $8 billion, positioning ORHub favorably within the PUR Biologics brand. The innovative design aims to improve patient outcomes by preventing graft material migration.

ORHub has announced the acquisition of PUR Biologics and the appointment of Ryan Fernan as its Head. Fernan, with over 18 years in the medical device and biotechnology sectors, previously led significant initiatives at major companies like Johnson & Johnson and Zimmer/Biomet. His expertise aims to enhance ORHub's position in the regenerative biologics market, targeting a therapy market worth over $40 billion annually. The move focuses on improving clinical outcomes while generating revenue through advanced ortho-spine solutions.

ORHub has launched its new Surgical Resource Management (SRM) platform, FutureOR, aimed at enhancing digitized connectivity and expediting vendor payments in the medical device sector. The platform is projected to cut the Case-to-Cash timeline by over 90%, targeting a market consisting of $2B+ in ortho-spine devices. The company anticipates onboarding 200 hospitals within 12 months. This initiative may significantly transform the payment processes and accountability for surgically implanted medical devices.

ORHub has announced the upcoming launch of its FutureOR application in Q3 2022, aimed at enhancing surgical implant accountability and improving business efficiency within the medical device sector. The company is expanding its partnership with Predica, which will provide managed services and support for this launch. FutureOR is expected to facilitate fast payments and streamline processes between hospitals and vendors, potentially reducing healthcare costs in the U.S. ORHub aims to reinforce its position as a finance-focused SaaS provider with this new platform.